Literature DB >> 29777842

Nationally Representative Readmission Factors in Patients with Claudication and Critical Limb Ischemia.

Rennier A Martinez1, Michelle Shnayder2, Joshua Parreco2, Lukas Gaffney2, Marcus Eby2, Nicholas Cortolillo2, Michael Lopez2, Jack Zeltzer2.   

Abstract

BACKGROUND: Hospital readmissions are associated not only with increased mortality, morbidity, and costs but also, with current health-care reform, tied to significant financial and administrative penalties. Some studies show that patients undergoing vascular surgery may have higher than average readmission rates. The recently released Nationwide Readmission Database (NRD) is the most comprehensive national source of readmission data, gathering discharge information from 22 geographically dispersed states, accounting for 51.2% of the total U.S. resident population and 49.3% of all U.S. hospitalizations. The aim of this study is to use the power of the NRD and obtain nationally representative readmission information for patients admitted with claudication or critical limb ischemia (CLI) who underwent revascularization procedures.
METHODS: The NRD was queried for all patients admitted for claudication (International Classification of Diseases Ninth Revision [ICD-9] 440.21) or CLI (ICD-9 440.22-440.24) and who underwent percutaneous transluminal angioplasty, peripheral bypass, or aortofemoral bypass. Patient demographics, comorbidities, length of stay (LOS), mortality, readmission rates, and associated costs were collected. Univariable and multivariable logistic regression analysis was implemented on claudication and CLI groups on all outcomes of interest. The most common readmission diagnosis codes and diagnosis groups were also identified.
RESULTS: A total of 92,769 patients were admitted for peripheral vascular disease (33,055 with claudication and 59,714 with CLI). The 30-day readmission/any readmission rate was 8.97%/21.49% and 19.26%/40.36%, for claudication and CLI, respectively. Significant differences were found for claudication and CLI, respectively, on initial cost of admission ($18,548 vs. $29,148, P < 0.001), readmission costs ($14,726 vs. $17,681 P < 0.001), LOS (4 days vs. 9 days, P < 0.001), days to readmission (73 days vs. 59 days, P < 0.001), mortality during initial admission (256 vs. 1,363, P < 0.001), and mortality during any admission (538 vs. 3,838, P < 0.001). Univariate and multivariate logistic regression analysis found that claudication, CLI, angioplasty, peripheral bypass, aortofemoral bypass, female sex, age >65, Charlson Comorbidity Index, LOS, and primary expected payer status were all significant predictors of 30-day and overall readmissions at varying degrees. The 5 most common disease readmission groups found were other vascular procedures (12.6%), amputation of lower limb except toes (6.3%), sepsis (5.4%), heart failure (4.9%) and postoperative or other device infections (4.8%). Of the abovementioned groups, the 4 most common diagnoses included "other postoperative infections," sepsis, atherosclerosis of native arteries with gangrene, and "other complications due to other vascular device, implant, or graft."
CONCLUSIONS: Our results demonstrate that there is a significant difference in readmission rates, cost, and morbidity between patients admitted for claudication and CLI. Furthermore, based on regression analysis, there are multiple other clear risk factors associated with worse clinical and economic outcomes. Further study is needed to predict which patients will require increased vigilance during their hospital stay to prevent readmissions and worse outcomes. LEVEL OF EVIDENCE: Care management/epidemiological, level IV.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29777842     DOI: 10.1016/j.avsg.2018.03.011

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  4 in total

1.  Chronic kidney disease and outcomes of lower extremity revascularization for peripheral artery disease.

Authors:  Nathaniel R Smilowitz; Nipun Bhandari; Jeffrey S Berger
Journal:  Atherosclerosis       Date:  2019-12-24       Impact factor: 5.162

2.  Extensive skeletal muscle cell mitochondriopathy distinguishes critical limb ischemia patients from claudicants.

Authors:  Terence E Ryan; Dean J Yamaguchi; Cameron A Schmidt; Tonya N Zeczycki; Saame Raza Shaikh; Patricia Brophy; Thomas D Green; Michael D Tarpey; Reema Karnekar; Emma J Goldberg; Genevieve C Sparagna; Maria J Torres; Brian H Annex; P Darrell Neufer; Espen E Spangenburg; Joseph M McClung
Journal:  JCI Insight       Date:  2018-11-02

3.  Mitochondrial Structure and Function in the Metabolic Myopathy Accompanying Patients with Critical Limb Ischemia.

Authors:  Thomas Groennebaek; Tine Borum Billeskov; Camilla Tvede Schytz; Nichlas Riise Jespersen; Hans Erik Bøtker; Rikke Kathrine Jentoft Olsen; Nikolaj Eldrup; Joachim Nielsen; Jean Farup; Frank Vincenzo De Paoli; Kristian Vissing
Journal:  Cells       Date:  2020-02-28       Impact factor: 6.600

4.  Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia.

Authors:  Shirli Tay; Gayan S De Silva; Connor M Engel; Nikolai Harroun; Amanda S Penrose; Kshitij A Desai; Yan Yan; Clay F Semenkovich; Mohamed A Zayed
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.